World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
37950
World Ranking
12962
National Ranking
6627

Overview

Chandra P. Belani is affiliated with the Penn State Cancer Institute in the United States. Their research primarily focuses on the fields of Medicine, with particular attention to Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Spectroscopy.

The scientist's main research themes encompass several specialized topics, including:

  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Research Studies
  • Advanced Proteomics Techniques and Applications
  • Mass Spectrometry Techniques and Applications

Chandra P. Belani's recent publications include significant contributions to the understanding and management of lung cancer. Notable works are:

  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer," 2021, Journal of Thoracic Oncology
  • "The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer," 2020, Journal of Thoracic Oncology
  • "Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic," 2020, Journal of Thoracic Oncology
  • "International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy," 2023, Journal of Thoracic Oncology
  • "Optimizing data-independent acquisition (DIA) spectral library workflows for plasma proteomics studies," 2022, PROTEOMICS

Frequent collaborators include:

  • Suresh S. Ramalingam
  • Giorgio V. Scagliotti
  • Murry W. Wynes
  • Shawn J. Rice
  • Madhusmita Behera

The scientist frequently publishes in the following venues:

  • Journal of Thoracic Oncology
  • JTO Clinical and Research Reports
  • UNC Libraries
  • PROTEOMICS
  • The Oncologist

Best Publications

  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

    Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

    Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim

  • Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

    Frank Fossella;Jose R. Pereira;Joachim von Pawel;Anna Pluzanska

  • Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

    Taofeek K. Owonikoko;Camille C. Ragin;Chandra P. Belani;Ana B. Oton

  • Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

    Roy S. Herbst;Vincent J. O'Neill;Louis Fehrenbacher;Chandra P. Belani

  • Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol

    Chandra P. Belani;Hak Choy;Phil Bonomi;Charles Scott

  • Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

    Suresh S. Ramalingam;Suzanne E. Dahlberg;Corey J. Langer;Robert Gray

  • Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

    Suresh Ramalingam;Chandra Belani

  • Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

    Christian Rolfo;Philip Mack;Giorgio V. Scagliotti;Charu Aggarwal

  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

    Mark A. Socinski;Silvia Novello;Julie R. Brahmer;Rafael Rosell

  • Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma

    Christopher J. Sweeney;Junming Zhu;Alan B. Sandler;Joan Schiller

  • Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer

    John V. Heymach;Bruce E. Johnson;Diane Prager;Edit Csada

  • Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

    Giorgio V. Scagliotti;Thomas Brodowicz;Frances A. Shepherd;Christoph Zielinski

  • A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

    Ramesh K. Ramanathan;Chandra P. Belani;Deepti A. Singh;Michael Tanaka

  • Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

    Chandra P. Belani;John Barstis;Michael C. Perry;Renato V. La Rocca

  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

    R.N. Patricia J. Hollen Ph.D.;Richard J. Gralla;Mark G. Kris;Christopher Cox

  • Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Suresh S. Ramalingam;Michael L. Maitland;Paul Frankel;Athanassios E. Argiris

  • Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

    Audrey Mauguen;Cécile Le Péchoux;Michele I. Saunders;Steven E. Schild

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Taofeek K. Owonikoko
Taofeek K. Owonikoko Emory University
Fadlo R. Khuri
Fadlo R. Khuri American University of Beirut
James D. Luketich
James D. Luketich University of Pittsburgh
David R. Gandara
David R. Gandara University of California, Davis
Xin Liu
Xin Liu Chinese Academy of Sciences
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
John C. Flickinger
John C. Flickinger University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re passionate about a career in medicine but want to explore alternative or supportive pathways, the healthcare field offers a wide variety of online degree options. Many professionals choose flexible online programs to advance their qualifications at their own pace.

Students interested in the highest levels of nursing may consider online dnp programs without clinicals, which can reduce time spent on in-person training and streamline the learning process for experienced nurses. Those who wish to enter the nursing profession quickly might explore fast track lpn programs—these are designed to help you become a Licensed Practical Nurse in less time.

Mental health is an in-demand specialty. The fastest psych np program options allow working nurses to efficiently specialize in psychiatric mental health, opening the door to new career opportunities.

Not every path leads to clinical roles. For those who prefer the business side of healthcare, an online healthcare administration programs can prepare you for leadership and management positions in hospitals, clinics, or other healthcare settings.

Best Scientists Citing Chandra P. Belani

Trending Scientists